Westbrook, Maine-based IDEXX Laboratories, Inc. (IDXX) is a global leader in veterinary diagnostics, software, and water testing solutions. Valued at a market cap of $52.5 billion, it develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries.
Companies worth $10 billion or more are typically classified as “large-cap stocks,” and IDXX fits the label perfectly. With its focus on innovation, digital solutions, and recurring diagnostic revenues, the company plays a key role in advancing animal health, food safety, and water quality worldwide.
Shares of the veterinary giant have decreased 4.7% from its 52-week high of $688.12, reached on Aug. 4. Shares of IDXX have soared 26.4% over the past three months, considerably outperforming the Health Care Select Sector SPDR Fund’s (XLV) 3.3% return during the same time frame.
www.barchart.com
In the longer term, IDXX stock has rallied 36.5% over the past 52 weeks, outpacing XLV’s 10.6% downtick over the same time period. Moreover, on a YTD basis, shares of IDXX are up 58.6%, compared to XLV’s marginal return.
To confirm its bullish trend, IDXX has been trading above its 200-day and 50-day moving averages since late April, with slight fluctuations.
www.barchart.com
On Aug. 4, shares of IDXX skyrocketed 27.5% after its strong Q2 2025 earnings release. The company reported revenue of $1.1 billion, up 10.6% year-over-year and 3.7% above the consensus estimates. Moreover, its EPS improved by an impressive 48.8% from the year-ago quarter to $3.63, topping analyst expectations by a notable margin of 9.7%. Noting its robust bottom-line performance, IDXX also raised its fiscal 2025 EPS outlook, further bolstering investor confidence. It now expects it to be between $12.40 and $12.76.
IDXX’s outperformance looks even more pronounced when compared to its rival, Zoetis Inc. (ZTS), which declined 21.9% over the past 52 weeks and 8.1% on a YTD basis.
Despite IDXX’s outperformance, analysts remain cautiously optimistic about its prospects. The stock has a consensus rating of “Moderate Buy” from the 12 analysts covering it, and the mean price target of $722.60 is a premium of 10.2% to current levels.
On the date of publication, Neharika Jain did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com